Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT06673238
PHASE1
A Study to Assess How the Drug Moves Through the Body, Adverse Events, and Tolerability of Oral ABBV-722 Capsules of Single and Multiple Ascending Doses in Adult Participants and Single Doses in Adult Asian Participants
Sponsor: AbbVie
View on ClinicalTrials.gov
Summary
This is a Phase 1, first-in-human study to investigate safety, tolerability, and pharmacokinetics of ABBV-722 after oral dosing in healthy adult participants.
Official title: A First-In-Human Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-722 Following Single and Multiple Ascending Doses in Healthy Adult Subjects and Single Doses in Healthy Adult Asian Subjects
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
96
Start Date
2024-10-29
Completion Date
2026-04
Last Updated
2025-07-20
Healthy Volunteers
Yes
Conditions
Interventions
DRUG
ABBV-722
Oral Capsule
DRUG
Placebo
Oral Capsule
Locations (1)
Acpru /Id# 270279
Grayslake, Illinois, United States